A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

Development of biosimilars in an era of oncologic drug shortages

(2015) Edward Li et al.   Drug Design Development and Therapy

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

(2014) J. Cortés et al.   BREAST CANCER RESEARCH AND TREATMENT

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)

(2014) Donghua Yin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers

(2014) Liselijn A. B. Wisman et al.   CLINICAL DRUG INVESTIGATION

New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer

(2014) Marc Thill   Expert Review of Anticancer Therapy

Trastuzumab-Induced Hepatotoxicity: A Case Report

(2013) Darko Vucicevic et al.   Breast Care

A Nation-Wide Multicenter Retrospective Study of the Epidemiological, Pathological and Clinical Characteristics of Breast Cancer In Situ in Chinese Women in 1999 - 2008

(2013) Yanan Kong et al.   PLoS One

Trastuzumab

(2011) A. H. Boekhout et al.   ONCOLOGIST

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

(2010) Daniela Cardinale et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Induced Hepatotoxicity

(2008) Sridhar Srinivasan et al.   ANNALS OF PHARMACOTHERAPY

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST